close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Olema Oncology

< Previous 1 2 3 Next >
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Upcoming Investor Conferences in June
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Upcoming Investor Conferences in May
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today